Pertuzumab biosimilar (Jushi Biopharmaceutical )

帕妥珠单抗生物类似药（石药集团巨石生物制药）

Report date: 2025/11/11 10:37:59

Base Information

Drug NamePertuzumab biosimilar (Jushi Biopharmaceutical )
Drug Alias NameSYSA1901SYSA-1901
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsMetastatic breast cancerBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesJushi Biopharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCspc Zhongqi Pharmaceutical Technology (Tianjin) Co LtdJushi Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A